Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 2

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 2
---
' equity per share (JPY) |          |
| As of March 31, 2025                  |     |               | 9,489,375 |     |               | 3,989,355 |     |                                | 42.0 |     |                                      | 2,534.39 |
| As of March 31, 2024                  |     |               | 9,756,319 |     |               | 4,088,198 |     |                                | 41.9 |     |                                      | 2,604.87 |

<div align='center'>(Reference) Shareholders' equity As of March 31, 2025 JPY 3,988,249 million

As of March 31, 2024 JPY 4,087,087 million</div>

#### ▪

#### Earnings report (

#### Kessan Tanshin
) is exempt from audit conducted by certified public accountants or an audit firm

#### ▪

Note to ensure appropriate use of forecasts and guidance, and other noteworthy items

| • |     | Takeda has adopted International Financial Reporting Standards (IFRS), and the disclosure information in this document is based on IFRS. |

| • |     | All forecasts and management guidance in this document are based on information and assumptions currently available to management, and do not represent a promise or guarantee to achieve these forecasts. Various uncertain factors could cause actual results to differ, such as changes in the business environment and fluctuations in foreign exchange rates. Should any significant event occur which requires the forecasts or guidance to be revised, Takeda will disclose it in a timely manner. |

| • |     | For details of the forecasts for consolidated operating results and the management guidance, please refer to "1. Financial Highlights for the Fiscal Year Ended March 31, 2025 (5) Outlook for the Fiscal Year Ending March 31, 2026" on page13. |

(Takeda Website):

https://www.takeda.com/investors/financial-results/

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

#### Attachment Index
| 1. Financial Highlights for the Fiscal Year Ended March 31, 2025                                               |     |  2 |
|:---------------------------------------------------------------------------------------------------------------|:----|---:|
| (1) Business Performance